Curtiss-Wright (CW) just caught fresh attention after being bumped up to a Zacks Rank 2, Buy rating, a shift that signals growing confidence in its earnings trajectory and underlying business momentum ...

The head of Xbox Game Studios, Matt Booty, has said that the company is continuing to evaluate how it prices its new releases. Speaking to Variety, the executive said that the firm hoped to "meet ...

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...

Lithium Americas (NYSE:LAC) -1.8% post-market Monday after Bloomberg reported the U.S. Department of Energy is re-evaluating a $2.3 billion loan approved during the Biden administration for the ...

BOUNTIFUL — Davis School District officials are evaluating the future of two dual-language immersion programs in district schools because of low participation. School representatives cited falling ...

A day after the CEO of the firm that is the sole finalist to build a new LSU arena was indicted in Texas, university officials said they are weighing how the criminal charges could affect the project ...

If you’re using Blink home security cameras and you don’t already have a Blink Sync Module 2, the Blink Sync Module XR delivers a host of benefits. I’m a big fan of security cameras with the capacity ...

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. This is an ASCO ...

– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – ...